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Background: The availability of the tyrosine-kinase inhibitor (TKI), imatinib, and later introduction of second
generation TKIs, dasatinib and nilotinib, have not only improved clinical outcomes of patients with chronic myeloid
leukemia (CML), but also provide multiple therapeutic options for CML patients. Despite the widespread use of
these oral therapies, little is known about the impact of different treatment regimens on patient-reported outcomes
(PROs) among CML patients. The objective of this study was to assess the impact of patient-reported treatment
restrictions and negative medication experiences (NMEs) on satisfaction and other health outcomes among patients
with CML treated with oral TKIs.
Methods: Participants recruited from survey panels and patient networks in the United States (US) and Europe
completed an online questionnaire. Respondents included adults (≥18 years) with chronic-phase CML currently
on TKI treatment. Study variables included treatment difficulty (i.e., difficulty in following treatment regimens),
CML dietary/dosing requirements, NMEs, and validated PROs assessing treatment satisfaction, health-related quality
of life (HRQoL), activity impairment, and non-adherence. Structural equation models assessed associations among
variables, controlling for covariates.
Results: 303 patients with CML (US n=152; Europe n=151; mean age 51.5 years; 46.2% male) completed the
questionnaire. Approximately 30% of patients reported treatment difficulties; treatment difficulty was higher among
nilotinib (63.3%) than among dasatinib (2.6%) or imatinib (19.2%) treated patients (p<0.0001). Non-adherence was
generally low; however, patients on nilotinib vs. imatinib reported missing doses more often (p<0.05). Treatment
satisfaction was associated with significantly increased HRQoL (p<0.05) and lower activity impairment (p<0.01).
NMEs were associated with decreased treatment satisfaction (p<0.01) and HRQoL (p<0.05), and greater activity
impairment (p<0.01). Higher overall treatment restrictions were associated with greater treatment difficulty
(p<0.001), which correlated with non-adherence (p<0.01).
Conclusions: Treatment satisfaction and NMEs are important factors associated with HRQoL among patients with
CML. Increased treatment restrictions and associated difficulty may affect adherence with TKIs. Choosing a CML
treatment regimen that is simple and conveniently adaptable in patients’ normal routine can be an important
determinant of HRQoL and adherence.
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Chronic myeloid leukemia (CML), a rare cancer, accounts
for approximately 15% of leukemia cases [1]. The estimated
number of new CML cases per year in the United States
(US) is 5,430, or 1.6 per 100,000 population in 2012 [2].
In Europe, crude incidence of CML is estimated to be
0.92 per 100,000 [3].
CML cells contain a BCR-ABL gene, not typically found
in normal cells, that produces a protein (BCR-ABL) causing
CML cells to proliferate [4]. CML occurs in three phases:
chronic, accelerated, and blast crisis. Disease staging is
primarily based on percent of blasts in the blood and
bone marrow. Most cases of CML are diagnosed in
chronic phase (CP) [4]. In CML-CP patients usually
have <10% blasts in their blood samples and the disease
can be controlled effectively with standard treatment,
with patients experiencing few or no symptoms [5,6].
Symptoms can include anemia-related fatigue, abdominal
pain, bleeding, bruising, and enlarged lymph nodes.
Accelerated phase patients are defined as experiencing
10-19% blasts [7] and patients progressing from CP to
accelerated phase CML experience a reduction in red
blood cells and platelets, fluctuations in white blood
cell count, an increase in blast cells, and swelling of
the spleen. According to the World Health Organization,
the definition of CML-blast phase includes patients who
have ≥20% blasts, while the blast crisis phase [7] differs
from the acceleration phase in that 30% or more blast
cells are found in the blood or bone marrow, and patients
may experience swelling of the liver, in addition to
symptoms present during earlier phases [4]. The blast
crisis phase is typically fatal [4].
A major objective in CML clinical management is to
prevent progression from chronic to accelerated and
blast crisis phases. While earlier treatments, such as
cytoreductive chemo- and interferon therapies increased
overall survival rates among patients, the advent of oral
tyrosine-kinase inhibitors (TKIs) has changed the CML
treatment landscape [8]. TKIs target the BCR-ABL
protein in CML cells and typically do not influence
normal cells, and they are usually associated with fewer
side effects compared with chemotherapy drugs or
interferon therapy [9]. Clinical trials of the first-generation
TKI, imatinib, demonstrate 5-year survival rates of at least
89% in patients in CP, transforming CML into a chronic
disease for many patients [8,10]. Second-generation oral
TKIs, dasatinib [11,12] and nilotinib [13], have provided
additional treatment options with superior cytogenetic
response compared with imatinib in clinical trials.
Bone marrow transplant (BMT) is considered a viable
treatment alternative for only a small subset of pediatric
and young adult chronic phase CML patients due to the
high risk of mortality and other serious complications
that can occur with this procedure [6]. Difficulties inprocuring suitable donors further preclude the broader
application of BMT for the treatment of CML [6]. In
patients for whom CML has progressed to either the
accelerated or blast crisis phases, however, allogeneic
hematopoietic stem cell transplantation is the primary
recommended treatment option [14].
Imatinib, dasatinib, and nilotinib are generally well
tolerated, but each has also been associated with side
effects that could potentially affect its use. Common
side effects for all three TKIs include nausea, fatigue,
and rashes [15]. Other side effects, including diarrhea,
fluid retention events, and headaches, have also been
reported [16-18]. Occurrence and persistence of such
side effects likely affect a patient’s perceived experience
with CML medication, potentially reducing adherence,
which consequently, may affect treatment outcomes [15].
With the widespread use of these oral TKIs in CP-
CML, burden of treatment administration has decreased
compared with previously used chemotherapy regimens;
however, daily administration is required for effective
management of CML [19]. Therefore, treatment satis-
faction, symptom, and/or side effect management become
important determinants of health-related quality of life
(HRQoL) and TKI treatment adherence. Furthermore,
understanding the overall patient experience with the
three TKIs is important given differences in labeled dosing
and administration requirements with respect to meal
timing and frequency of dosing [16-18].
The need to measure patient-reported outcomes (PROs)
to help guide treatment decisions, especially for currently
available TKIs, has been highlighted in the literature
[20]. However, few studies have assessed PROs in a
real-world setting [21], and the effects of long-term oral
CML treatment on patient-reported HRQoL have not
been explored comprehensively [6]. Efficace et al. [22]
found that patients with CML on long-term imatinib
therapy exhibited HRQoL comparable to that of the gen-
eral population. Younger (aged 18–39) vs. older patients
experienced significant activity limitations resulting from
physical and emotional impairments. Likewise, female
vs. male patients experienced lower HRQoL, indicating
fatigue as the most frequent symptom [22].
This study was conducted to better understand the
impact of different dosing aspects of TKI treatment on
treatment satisfaction, HRQoL, adherence, and activity
impairment. The primary objective was to assess, from
the patient’s perspective, the impact of CML treatment
restrictions, dosing administration, and negative medication
experiences (NMEs) on overall treatment satisfaction
for each of the three oral TKIs (imatinib, dasatinib, and
nilotinib). The study further explored the impact of
treatment satisfaction and NMEs on adherence, HRQoL,
and activity impairment. A secondary objective was to
examine the impact of different treatment restrictions
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oral TKI regimen and its impact on patient-reported
non-adherence among patients with CML.
Methods
Data source and sample
The study population consisted of 303 patients reporting
a physician diagnosis of CML in the US and Europe
(UK, France, Germany, Spain, and Italy). Ninety-seven
respondents (32%) in the US were identified using
NexCura’s recruitment services. NexCura maintains a
database of more than 1,000,000 patients with cancer,
cardiovascular, and respiratory diseases. NexCura provides
educational tools to patients visiting health information
websites (e.g., the American Cancer Society [cancer.org]).
All potential panelists must register with the panel
through a unique email address and password and
complete an in-depth demographic registration profile
they routinely update. Participants of the current study
were sent an invitation to participate in the web-based
questionnaire. An additional 55 US respondents (18.2%)
and all 151 (49.8%) European respondents were recruited
via telephone through interview facilities, including
panel recruiting, grassroots campaigns, and newspaper
advertising and physician referrals of patients diagnosed
with CML.
Eligible study participants included adults (≥18 years)
with self-reported diagnosis of CP-CML who were
currently on, or on a drug holiday from, oral TKI
treatment (imatinib, dasatinib, or nilotinib). Respondents
were excluded if they were: 1) currently in accelerated
or blast phase of CML or not sure of their current
CML phase, 2) not currently being treated with an oral
TKI, with no intent of initiating or resuming treatment,
or 3) unsure about their current treatment. To ensure
PROs appropriately represented the treatment experience
of patients with CML, patients diagnosed with any cancer
other than CML were excluded.
Data were collected from November 2010 through
May 2011 via an online patient questionnaire. The
questionnaire was developed with input from an advisory
board comprising opinion leaders and health care profes-
sionals from the US (n=3) and Europe (n=2). The advisory
board independently reviewed the item pools and helped
establish face validity and content validity for the patient
questionnaire. The patient questionnaire was also piloted
in a sub-sample of patients with CP-CML (n=20). The 20
patients with CML participated in an in-depth telephone
interview (approximately 45 minutes in length). To ensure
consistency in the tone and presentation of the questions,
a single moderator conducted all 20 interviews. Data
generated from a literature review and the pilot interviews
were used to identify the key constructs to be included
in the final survey instrument. The study was reviewedand approved by Essex IRB (Lebanon, NJ), and all study
participants provided their informed consent prior to
participation. Participants were provided with incentives
for their completion of the survey.
The questionnaire incorporated validated PRO in-
struments, plus 52 questions focused on ascertaining
overall CML disease status, treatment burden, treatment
satisfaction, non-adherence, and the physician-provider
relationship.CML treatment
CML treatment-related variables included: 1) CML treat-
ment restrictions, 2) number of CML treatment doses
per day, and 3) NMEs. Treatment restrictions included
specific dietary restrictions and dosing requirements and
were identified according to TKI label instructions. Dietary
restrictions included the need to take the CML medication
while fasting (i.e., on an empty stomach), with food,
without certain foods (i.e., grapefruit juice), with water,
dissolved in water and taken immediately, or without
certain non-CML medications. Dosing requirements
included taking the medication once each day, twice each
day, taking two or more pills at one time, and taking pills
at specific times of day or at specific hours apart (e.g., 12
hours).
To quantify the incremental burden associated with
increased CML treatment doses per day, a continuous
variable was used to indicate the number of times a day
an oral TKI was taken, measured using a single item:
“Thinking about a typical day, how many times do you
take your current CML treatment?”
To identify NMEs associated with TKI treatment,
patients were asked to identify whether they experienced
any of 34 symptoms associated with CML disease and
treatment in the past 4 weeks. If participants reported
experiencing at least one NME in the past 4 weeks
(experience component), they were further asked to
identify which NMEs were the most bothersome (Yes/
No; bothersome component), and which NMEs had
the biggest impact on patients’ ability to go about their
normal routine (Yes/No; impact component).Satisfaction with treatment and health outcomes
Overall satisfaction with current CML treatment was
assessed using the Satisfaction with Therapy component
of the Cancer Therapy Satisfaction Questionnaire (CTSQ)
[23,24]. Respondents were asked about the difficulty of
following specific CML treatment restrictions or require-
ments: “Would it be easier for you to follow your CML
treatment regimen if you did not need to follow the
specific dietary restrictions or requirements?” (Yes/No).
Individuals who did not report any treatment restrictions
did not complete this questionnaire item but were coded
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improvement over their current regimen.
HRQoL was assessed using Physical and Mental Com-
ponent Summary (PCS, MCS) scores from the Medical
Outcomes Study 12-Item Short Form Survey Instrument
(SF-12v2), a multipurpose, generic HRQoL instrument
[25]. The SF-12v2 is a validated, shortened version of the
SF-36v2, which has been used previously as an HRQoL
measure by Efficace et al. in patients with CML [22].
The SF-12v2 was deemed the appropriate choice for the
current study, limiting the length of the overall survey
while obtaining reliable generic measures of mental and
physical health status and overall HRQoL on a scale that
can be understood and compared across various comorbid
conditions and populations. MCS and PCS scores have a
normed mean of 50 and a standard deviation of 10 for the
U.S. population. Health utilities were calculated using the
SF-6D algorithm, which provides a preference-based
single index measure for health, referenced to general
population values, with interval scores on a theoretical
0–1 scale [26]. Activity impairment was assessed using
the Work Productivity and Activity Impairment (WPAI)
validated instrument [27], which consists of four subscales,
generated in the form of percentages, with higher values
indicating greater impairment. As data for absenteeism,
presenteeism, and overall work impairment subscales were
available only for employed respondents, only activity
impairment was included in the analyses.
CML treatment adherence
To understand how well respondents adhered to their
current medication, patient-reported non-adherence was
assessed: “In the past 4 weeks, how many doses of your
current CML treatments have you missed, intentionally
or unintentionally?” Similar questions ascertained how
many doses patients skipped and took less than the
product label-prescribed amount in the past 4 weeks.
Higher number of doses missed, skipped, or taken in
reduced amounts indicated a greater degree of non-
adherence to CML treatment.
Control variables
Additional analytical control variables included the number
of non-CML medications taken per day (i.e., treatment
for other diseases) and patient demographics and health
characteristics. The number of non-CML medications
taken per day was evaluated by one item: “Excluding
your CML treatments, how many medications for all
other conditions do you take on a daily basis? Include
both prescription and over-the-counter medications.”
Patient demographics and health characteristics included
gender, age, time since CML diagnosis by a physician, time
on current treatment, and self-reported co-morbidities
(the complete list of co-morbidities included 32 conditions,which could be a result of treatment, disease complications,
neither, or both).
Statistical analyses
Participants were initially categorized according to self-
reported CML treatment (imatinib, dasatinib, nilotinib,
or other/decline to answer). Descriptive analyses of patient
demographics and health characteristics were performed
for the full study sample. Bivariate analyses for differences
across patients’ current CML treatment were evaluated
using Chi-square tests for categorical variables and
independent sample t-tests for continuous variables.
Structural equation modeling
A multivariate model was developed, using structural
equation modeling (SEM), to assess interrelationships
among the main explanatory CML treatment-related vari-
ables, treatment satisfaction, and identified PRO variables.
To explore the secondary objective, an additional model
was developed, assessing the associations between treat-
ment restrictions, treatment difficulty, and non-adherence.
Non-adherence was modeled as an unobserved latent
factor, represented by missing, skipping, and taking fewer
doses than recommended. NMEs were also modeled as
a latent factor, represented by impact, bothersome, and
experience subcomponents. Modeling these as latent
factors allowed for an examination of the degree to which
latent factors were represented by their components.
Standardized estimates for these models indicated direc-
tion and strength of association between: 1) composite
variables and their individual components (e.g., the degree
to which observed components reflect the latent factor of
non-adherence), and 2) explanatory and outcome variables
(i.e., as in most regression models). Regression estimates
are interpretable in a similar manner as correlation coeffi-
cients (range of −1 to +1, with 0 indicating no relation-
ship). Straight arrows in the model represent (causal)
regression estimates, and curved arrows represent correla-
tions (associations). P-values, based upon unstandardized
estimates, indicate statistical significance of those estimates.
Item response theory modeling
To help simplify and consolidate complex information
for CML treatment restrictions and the three subgroups
of NMEs, given the large groups of interrelated items
composing each variable, item response theory (IRT)
models were used to create summary scores. IRT is a
statistical theory that describes the association between
where a respondent lies on the continuum of some
unobserved variable and the probability of a particular
item response [28,29]. Three separate IRT models were
created for NMEs, reflecting the experience, bothersome,
and impact items to define a higher-order NMEs variable
used in SEM. An IRT model was created for CML
Table 1 Demographics and clinical characteristics of
CML cohort
Total CML-CP
Patients (n=303)
Gender (n, %)
Male 140 (46.2%)
Female 163 (53.8%)
Age (mean years, SD) 51.5 (±13.6) years
Time since CML diagnosis (mean years, SD) 4.8 (±4.5) years
Time since CML diagnosis (n, %)
<2 years 76 (25.1%)
2 to <5 years 90 (29.7%)
≥ 5 years 136 (44.9%)
Unknown 1 (0.3%)
Country (n, %)
USA 152 (50.2%)
Italy 37 (12.2%)
Germany 33 (10.9%)
Spain 32 (10.6%)
United Kingdom 25 (8.3%)
France 24 (7.9%)
Time on Current CML Treatment (median years, IQR) 2.75 (4.8)
Current CML Treatment (n, %)
Imatinib 208 (68.6%)
Nilotinib 49 (16.2%)
Dasatinib 38 (12.5%)
Other 4 (1.3%)
Decline to answer 4 (1.3%)
No. of Comorbidities (mean, SD) 1.4 (±2.4)
Comorbidities (n, %)
Hypertension 49 (16.2%)
Insomnia/sleep difficulties 32 (10.6%)
Depression 25 (8.3%)
Arthritis 24 (7.9%)
Anxiety 24 (7.9%)
Anemia 21 (6.9%)
Note: CML=Chronic Myeloid Leukemia, CP=Chronic Phase, SD=Standard
Deviation, IQR=Inter Quartile Range.
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treatment restrictions and dosing requirements, where
higher scores indicated greater restrictiveness.
Model fit assessments
The structural equation models were developed and
tested using Mplus version 6.1 [30], and IRT models
were created using R software (www.R-project.org).
Acceptability of the overall fit of the SEM regressions
was assessed using the Chi-square test and values of
the Comparative Fit Index (CFI), Tucker-Lewis Index
(TLI), and Root Mean Square Error of Approximation
(RMSEA) statistics [31-33]. For the Chi-square test,
good model fit was demonstrated by Chi-square values
divided by degrees of freedom (relative Chi-square)
that were close to or lower than 2, and non-significant
associated p-values. Higher CFI and TLI values ap-
proaching 1 indicated a better fit (e.g., 0.95 and higher),
whereas lower RMSEA values (i.e., below 0.06) were
considered a good model fit.
Results
Baseline demographics and clinical characteristics
The study population consisted of 303 adults diagnosed
with CML across the US (n=152), United Kingdom
(n=25), France (n=24), Germany (n=33), Italy (n=37), and
Spain (n=32). Among all respondents, 68.6% reported
current treatment as imatinib (US: n=102, EU: n=106),
12.5% dasatinib (US: n=25, EU: n=13), 16.2% nilotinib
(US: n=22, EU: n=27), and 2.7% reported other/decline to
answer (US: n=1, EU: n=3) (Table 1). Mean age was 51.5
years (SD=13.6), 46.2% were male, and mean time since
diagnosis was 4.8 years (SD=4.5), with 12.3% reporting
being within 12 months of diagnosis. One respondent
was missing information on length of time since diagnosis
and was excluded from analyses involving this variable.
Mean number of comorbidities was 1.4 (SD=2.4), with
the most common being hypertension (16.2%), insomnia/
sleeping difficulties (10.6%), and depression (8.3%). In the
US the average age was 51.5 years (SD=11.9); 38.2% were
male and the average time since diagnosis was 4.8 years
(SD=3.8). In Europe the average age was 51.6 years
(SD=15.1); 54.3% were male, and the average time since
diagnosis was 4.9 years (SD=5.1). All other US and EU
patient characteristics and clinical measures were similar
for respondents (data not shown).
CML treatment restrictions
Fewer patients on dasatinib reported having to take their
pills with food (36.8% vs. imatinib: 70.2%; p<0.01) or water
(39.5% vs. imatinib: 63.0% & nilotinib: 65.3%; p<0.02;
Table 2). Patients on nilotinib reported the following
treatment restrictions more frequently than patients on
dasatinib and imatinib: take medication while fasting(p<0.01), at specific hours apart (p<0.01), not take with
certain foods (p<0.01), take twice each day (p<0.01), and
take two or more pills at one time (p<0.01). Patients on
nilotinib also reported taking their pills with food less
frequently than patients on dasatinib (4.1% vs. 36.8%;
p<0.01).
Based on the IRT model, the requirements of taking
medication with water or food were at the low end of
the restrictions scale (representing “easier” items), whereas
Table 2 CML treatment restrictions, negative medication experiences, and overall disease burden, according to current
CML treatment
Imatinib Dasatinib Nilotinib Imatinib vs.
Dasatinib
Imatinib vs.
Nilotinib
Dasatinib vs.
Nilotinib(N=208) (N=38) (N=49)
N % N % N % p-value p-value p-value
Treatment Restrictions
Dietary Restrictions
While fasting 5 2.40% 0 0.00% 42 85.71% 0.33 <.01 <.01
With food 146 70.19% 14 36.84% 2 4.08% <.01 <.01 <.01
Without certain foods 88 42.31% 16 42.11% 36 73.47% 0.98 <.01 <.01
With water 131 62.98% 15 39.47% 32 65.31% <.01 0.76 0.02
Dissolve tablets in water and drink immediately 3 1.44% 0 0.00% 1 2.04% 0.46 0.76 0.38
Without other non-CML medications 22 10.58% 2 5.26% 9 18.37% 0.31 0.13 0.07
Dosing Requirements
Once each day 105 50.48% 17 44.74% 3 6.12% 0.52 <.01 <.01
Twice each day 15 7.21% 5 13.16% 32 65.31% 0.22 <.01 <.01
Two or more pills at one time 26 12.50% 3 7.89% 24 48.98% 0.42 <.01 <.01
At specific times of the day 101 48.56% 19 50.00% 31 63.27% 0.87 0.06 0.22
At specific hours apart 32 15.38% 7 18.42% 38 77.55% 0.64 <.01 <.01
Mean SD Mean SD Mean SD p-value p-value p-value
Treatment Restriction Score −0.06 0.69 −0.31 0.77 0.61 0.68 0.06 <.01 <.01
No. Treatment Doses (times per day) 1.20 0.50 1.32 0.62 1.88 0.39 0.27 <.01 <.01
Negative Medication Experience
Experienced Score 0.06 0.90 −0.10 0.98 0.07 0.91 0.35 0.96 0.42
Bothersome Score 0.02 0.70 0.10 0.62 0.07 0.74 0.47 0.66 0.83
Impact Score 0.02 0.66 0.10 0.57 0.11 0.65 0.45 0.38 0.93
No. Non-CML Medications per day 2.02 2.67 2.47 4.07 2.27 2.77 0.52 0.58 0.79
Time since CML diagnosis (years) 4.85 4.31 5.32 4.47 3.69 4.14 0.55 0.09 0.09
Time on Current CML Treatment (years) 4.60 2.98 2.07 1.69 1.55 1.35 <.01 <.01 0.12
No. Comorbidities 1.17 2.13 1.97 3.19 1.59 2.71 0.14 0.32 0.56
Note: CML=Chronic Myeloid Leukemia, No.=Number of, SD=Standard Deviation.
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non-CML medication or taking medication while fasting
were at the high end of the scale (representing more
“difficult” items). Overall CML treatment restriction
scores ranged from −1.33 to 1.60, with positive values
indicating greater restrictiveness. Average scores were low
among patients on dasatinib (Mean=−0.31, SD=0.77)
and patients on imatinib (Mean=−0.06, SD=0.69), whereas
average scores were significantly higher among patients
on nilotinib (Mean=0.61, SD=0.68; p<0.01).
Number of CML treatment doses (times per day)
The dosing regimens approved by the Food and Drug
Administration (FDA) are 2 per day for nilotinib, 1 per
day for dasatinib, and either 1 or 2 per day for imatinib
[16-18]. Consistent with these guidelines, patients on
nilotinib reported having to take their CML medicationsignificantly more times per day (Mean=1.88, SD=0.39),
compared with patients on dasatinib (Mean=1.32, SD=0.62)
and imatinib (Mean=1.20, SD=0.50; p<0.01).
NMEs
No significant differences were found across the three
TKIs on the average scores for experiencing NMEs or
perceiving them as being bothersome or having an impact
on patients’ daily routine (Table 2).
Control variables
There were no significant differences in the total number
of non-CML medications taken per day, time since CML
diagnosis, and the number of comorbidities across the
three TKI groups. Patients on imatinib had used their
current treatment for a significantly longer duration
(Mean=4.60 years, SD=2.89) than patients on dasatinib
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years, SD=1.35; p<0.01).
Treatment difficulty
Significantly more patients on nilotinib reported having
difficulty taking their CML medication (n=31, 63.3%),
compared with patients on imatinib (n=40, 19.2%; p<0.01)
and dasatinib (n=1, 2.6%; p<0.01) (Table 3). Patients on
dasatinib represented the smallest proportion of those
reporting having difficulty taking their CML medication
(p≤0.01 vs. imatinib and nilotinib).
Satisfaction with CML treatment, HRQoL, and
activity impairment
CTSQ results indicated that CML patients were generally
satisfied with their treatment (total, Mean=83.7, SD=14.4).
No significant differences emerged for satisfaction with
treatment across the three TKIs. Similarly, no significant
differences emerged for MCS, PCS, health utilities, and
activity impairment, across TKIs (data not shown).
CML treatment adherence
The majority of patients reported being adherent to their
CML treatment, with 34% (n=103) reporting having
missed (unintentional) or skipped (intentional) doses, or
having taken fewer doses than prescribed within the
past 4 weeks. However, patients on nilotinib (Mean=1.02,
SD=1.60) reported missing their doses significantly
more often than imatinib users (Mean=0.45, SD=1.08;
p<0.05).
Multivariate models using SEM for total sample (n=302)
SEM results examining the associations of CML treatment
restrictions, dosing requirements, NMEs, CML treatment
satisfaction, and PROs are shown in Figure 1. Fit statistics
indicate a fair fit of the model to the data (χ2=408.8,
degrees of freedom=76, p-value<0.01; CFI=0.79; TLI=0.63;
RMSEA=0.12).Table 3 Treatment difficulty and non-adherence among CML
Imatinib Dasatinib
(N=208) (N=38)
Mean, N SD, % Mean, N SD, %
Treatment Difficulty
Yes 40 19.23% 1 2.63%
No 168 80.77% 37 97.37
Non-Adherence
No. Missed Doses 0.45 1.08 0.63 1.73
No. Skipped Doses 0.41 1.53 0.53 1.83
No. Doses Less than Prescribed 0.10 0.52 1.05 4.78
Note: CML=Chronic Myeloid Leukemia, No.=Number of, SD=Standard Deviation.CML treatment restrictions were not significantly
associated with self-reported non-adherence (beta=0.07,
p=0.42) or satisfaction with treatment (beta=0.10, p=0.07).
However, the number of CML treatment doses (times
per day) were significantly negatively associated with
treatment satisfaction (beta=−0.12, p=0.03), indicating
that as the number of treatment doses increased, satis-
faction with treatment decreased.
Satisfaction with treatment was a direct predictor of
higher PCS (beta=0.19, p<0.01), MCS (marginally, at
p=0.05), and health utility scores (beta=0.20, p=0.02), and
lower activity impairment (beta=−0.28, p<0.01), adjusting
for the effect of age, gender, co-morbidities, time
since diagnosis, and non-CML medications. Satisfaction
with treatment was not a significant predictor of non-
adherence (p=0.31).
NME was a strong predictor of lower satisfaction with
treatment (beta=−0.37, p<0.01), PCS (beta=−0.36, p<0.01),
MCS (beta=−0.48, p=0.01), and health utility scores
(beta=−0.52, p<0.01), and greater activity impairment
(beta=0.59, p<0.01), after adjusting for aforementioned
covariates. NME was not a significant predictor of non-
adherence (p=0.95). There were strong direct, deleterious
effects of NME on the PROs, as well as more moderate
indirect (mediated) effects via satisfaction with treatment
that accounted for at least 10% of the total relationship
between NME and the PROs.
The model covariates—age, gender, number of comor-
bidities, years since diagnosis, and number of non-
CML medications—were not significantly associated
with non-adherence (p≥0.23 for all; data not shown).
A second multivariate model, also using SEM, further
examined inter-relationships between CML treatment
restrictions, patient-reported treatment difficulty, and
non-adherence (Figure 2). Given that none of the above-
mentioned covariates were significantly associated with
non-adherence in the first model, these were excluded
to retain maximum statistical power. Fit statistics indicated
a good fit of the model to the data, given the high CFIpatients, according to current CML treatment
Nilotinib Imatinib vs.
Dasatinib
Imatinib vs.
Nilotinib
Dasatinib vs.
Nilotinib(N=49)
Mean, N SD, % p-value p-value p-value
31 63.27% 0.01 <.01 <.01
% 18 36.73% 0.01 <.01 <.01
1.02 1.60 0.54 0.02 0.29
0.73 1.62 0.72 0.21 0.58
0.47 1.46 0.23 0.08 0.47
Activity Impairment
Health Utilities
Satisfaction with Treatment
Negative Medication 
Experience
Non-Adherence
Number of CML 
Treatment Doses (times 
per day)
Physical Component Summary 
(PCS)
Mental Component Summary 
(MCS)
Doses Missed Doses 
Skipped
Less than 
Prescribed
Impact Bothersome Experience
CML Treatment 
Restrictions
Number of non-CML 
Medications Taken per 
Day
0.63
(p=0.01)
0.28
(p<0.01)
0.57
-0.12
(p=0.03)
0.07
(p=0.23)
0.10
(p=0.07)
0.14
(p=0.06)
0.07
(p=0.42)
-0.09
(p=0.31)
-0.48
(p=0.01)
-0.37
(p<0.01)
Figure 1 Multivariate structural equation model predicting the associations of CML treatment restrictions, treatment doses, NME, CML
treatment satisfaction, and patient-reported outcomes among CML patients. Note. The following covariates or non-significant predictors (of
adherence, activity impairment, MCS, PCS, and health utilities) are not presented: age, gender, number of comorbidities, time since diagnosis, and
number of non-CML medications taken per day. Straight lines indicate betas and curved lines indicate correlations. Residual error terms,
estimated for all predicted variables and factors, are not presented; neither are correlation estimates. Non-parenthetical values are standardized
estimates (ranging from −1 to +1, with 0 = no effect) indicating strength and direction of association; these values can be compared across
predictors. P-values are based on the unstandardized path estimates. No p-values are available for the first indicators per factor, which set the
scale. Fit statistics indicate a fair fit of the data to the model (χ2 test of model fit=408.8; df=76; p-value<0.01. CFI=0.79; TLI=0.63; RMSEA=0.12).
CML = chronic myeloid leukemia, NME = negative medication experience.
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grees of freedom=10, p-value<0.01; CFI=1.00; TLI=1.01;
RMSEA<0.01).
Higher overall CML treatment restriction scores were
associated with significantly greater difficulty in taking
medication as prescribed (beta=0.28, p<0.01). Self-reported
treatment difficultly and non-adherence were highly
positively correlated (r=0.22, p<0.01). Therefore, as treat-
ment difficulty increased, non-adherence increased. CML
treatment restrictions were not significantly, directly
associated with non-adherence (p=0.26).
Discussion
Oral TKIs have revolutionized treatment options for
patients with CML, enabling a shift in focus from im-
proving survival to improving PROs. The present study
is one of the few that evaluate how CML treatment
characteristics and symptoms can affect outcomes from
the patient’s perspective. After adjusting for patient
characteristics, patients’ negative experience with their
CML medication was a strong determinant of theiroverall treatment satisfaction. Additionally, greater NME
and lower satisfaction with treatment were associated
with significantly increased activity impairment. Further-
more, lower NME and greater treatment satisfaction were
associated with significantly greater HRQoL. Considering
that patients with CML are required to take daily, life-long
treatment to manage their disease, optimizing satisfaction
with current oral treatment options plays an important
and direct role in improving the well-being of patients
with CML.
Whereas CML treatment restrictions were not signifi-
cantly associated with treatment satisfaction and non-
adherence overall, having to take CML treatments more
than once a day (i.e., nilotinb and imatinib) did have a
significant negative association with patient satisfaction
with treatment (as noted previously, nilotinib should be
taken twice per day and imatinib taken once or twice
per day). Consistent with this observation, increased
restrictions in CML treatment were associated with
patient-reported difficulty following these treatment
restrictions or requirements, which, in turn, was associated
Taking Less than PrescribedSkipping DosesMissing Doses
CML Treatment Restrictions
0.26 (p=0.01)0.51 (p<0.01)0.70
0.09 (p=0.26)
Non-Adherence
0.22 (p<0.01)
0.28 (p<0.01)
Treatment Difficulty
Figure 2 Multivariate structural equation model predicting the associations of CML treatment restrictions, patient reported difficulty
following CML treatment, and non-adherence among CML patients. Note. Straight lines indicate betas and curved lines indicate correlations.
Residual error terms, estimated for all predicted variables and factors, are not presented. Non-parenthetical values are standardized estimates
(ranging from −1 to +1, with 0 = no effect) indicating strength and direction of association; these values can be compared across predictors.
P-values are based on the unstandardized path estimates. No p-values are available for the first indicators per factor, which set the scale. Fit
statistics indicate a good fit of the data to the model (χ2 test of model fit=91.6; df=10; p-value<0.01. CFI=1.0; TLI=1.01; RMSEA<0.01). CML = chronic
myeloid leukemia.
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to treatment. Eliasson et al., found both intentional and
unintentional reasons for non-adherence to imatinib, with
patients being unaware that non-adherence could result
in a negative clinical response [34]. Factors predicting
adherence to imatinib therapy are group assistance,
being informed, concomitant drug burden, managing side
effects, and reminders to take the medicine [34-36].
Continuous and adequate dosing is essential to patient
success on CP-CML therapy; however, many struggle to
remain adherent to treatment. Among patients with CML,
adherence to treatment correlates with the probability of
achieving an improvement in long-term clinical outcomes,
including major molecular response and improved event-
free survival [37-39]. Therefore, choosing a regimen that
can be adapted conveniently in patients’ normal routine,
with minimal disturbance, is an important consideration
for treatment choice and adherence.
Corresponding with general labeling instructions,
patients on dasatinib were less likely to report certain
dietary and dosing restrictions than patients taking
nilotinib or imatinib. For example, imatinib should be
taken along with food and water, whereas nilotinib
should be taken at least two hours after and one hour
before food consumption. Dasatinib, on the other
hand, should be taken with water, but can be taken
with or without food. Whereas imatinib and dasatinib
can be taken once daily, nilotinib needs to be taken
twice daily, approximately 12 hours apart [16-18]. As
the present study mainly focused on understanding the
overall treatment burden among patients with CP-CML,the study did not achieve sufficient sample size of
dasatinib and nilotinib users to facilitate direct drug-to-
drug comparisons of HRQoL outcomes. Nevertheless,
the results of this study suggest that certain treatment
restrictions and disease-related symptoms are important
determinants of PROs among patients with CML. Spe-
cifically, based on the IRT model, the requirement of
having to take medications while fasting (i.e., nilotinib)
was considered by patients as being more “difficult,”
whereas taking medications regardless of meals/water
intake (i.e., dasatinb, imatinib, and nilotinib) was consid-
ered “easier.” Treatment restrictions (and corresponding
treatment difficulty) are burdensome to patients, which
ultimately may affect adherence. Further research is needed
to understand whether differences in characteristics of
available TKIs may give rise to different HRQoL out-
comes across these therapies.
The present research is the first to provide a multivari-
ate model of the complex inter-relationships between
patient treatment satisfaction, disease-related symptoms,
and HRQoL outcomes among a geographically diverse
sample of patients with chronic-phase CML in the US and
Europe. Nevertheless, the study has certain limitations.
The findings may be limited by potential inaccuracies
in participants’ recollections regarding medical diagnoses
and other study variables. Further studies should gather
more objective measures of diagnosis and treatment
information from patient medical records and adherence
data, to corroborate any self-reported data. The survey for
the current study was administered between late 2010 and
early 2011, during which time bosutinib and ponatinib did
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therefore, no data were available or analyzed for these new
TKIs. The use of a cross-sectional design precludes the
ability to draw causal inferences (for example, although
it is assumed that treatment satisfaction has a more
substantial effect on HRQoL than vice versa, both
reverse causation and other causal explanations cannot
be ruled out). It would, therefore, be instructive to perform
repeated measures or longitudinal analyses not only to
replicate the current findings but also to determine
whether there are fluctuations in CP-CML outcomes over
longer periods of time. Non-adherence was measured
using three distinct questions (skipping, missing, and
taking less medication than prescribed); given that
these items have not been validated, further research is
needed to estimate their reliability and validity vis-à-vis
existing, validated measures of adherence and non-ad-
herence. The HRQoL measure (SF-12v2) included in
the current study was generic, not specific to cancer.
Therefore, whereas the SF-12v2 captured the potential
overall impact of treatment, it may have been relatively
less sensitive to detecting cancer-specific differences
and may have underestimated those effects. Lastly, there is
always the possibility for omitted variable bias if important
explanatory variables are not accounted for in the model.
Fit statistics for the present multivariate models indicated
a fair to good model fit (Figures 1, 2), suggesting that
additional variability in the data may not be accounted
for by the hypothesized model. Additional research is
needed to better understand other characteristics that may
affect PROs and non-adherence beyond those assessed in
the current study.
Conclusion
In conclusion, the results of this study demonstrate that
both treatment satisfaction and NMEs with oral TKIs
are important factors that can affect HRQoL among pa-
tients with CML. In addition, treatment restrictions are
associated with patient-reported difficulty in following
prescribed treatment regimens, which in turn, may affect
adherence with TKI treatment. Continuous and adequate
dosing is essential to patient success on CP-CML therapy;
however, many struggle to remain adherent to treatment.
Choosing an oral treatment regimen that can be adapted
conveniently in patients’ normal routine may be an
important determinant of HRQoL and adherence among
patients with CML.
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